TP53 and osteoarthritis: In fact, local treatment with UBX0101 selectively kills SnCs in mice with post-traumatic osteoarthritis and Unity Biotechnology advanced this compound to clinical trials for the treatment of this pathology (Table 1); however, the Phase 2 clinical trial for osteoarthritis did not result in statistical significance compared with the placebo; therefore, the development of more efficient and safer approaches to activate p53 without causing significant tissue toxicity is still required.